CD271/p75NTR is a novel diagnostic marker, prognostic indicator and therapeutic target in SHH medulloblastoma

GSE107701 CD271/p75NTR is a novel diagnostic marker, prognostic indicator and therapeutic target in SHH medulloblastoma: Contributors : Lisa Liang ; Ludivine Coudière Morrison ; Nazanin Tatari ; Margaret Stromecki ; Agnes Fresnoza ; Christopher J Porter ; Marc Del Bigio ; Cynthia Hawkins ; Jennifer Chan ; Michael D Taylor ; Vijay Ramaswamy ; Tamra Werbowetski-Ogilvie

Series Type : Expression profiling by high throughput sequencing

Organism : Homo sapiens

The extensive heterogeneity both between and within the medulloblastoma (MB) subgroups underscores a critical need for variant-specific biomarkers and therapeutic strategies. We previously identified a role for the CD271/p75 neurotrophin receptor (p75NTR) in regulating stem/progenitor cells in the SHH MB subgroup. Here, we demonstrate the utility of CD271 as a novel diagnostic and prognostic marker for SHH MB using immunohistochemical analysis as well as transcriptome data across 763 primary tumors. Characterization of CD271+ and CD271- cells by RNA sequencing revealed that these two subpopulations are molecularly distinct, co-existing cellular subsets both in vitro and in vivo. MAPK/ERK signaling is upregulated in the CD271+ population and inhibiting this pathway reduced CD271 levels, stem/progenitor cell proliferation and cell survival as well as cell migration in vitro. Importantly, the MEK inhibitor selumetinib extends survival and reduces CD271 levels in vivo. Our study demonstrates the clinical utility of CD271 as both a diagnostic and prognostic tool for SHH MB tumors and reveals a novel role for MEK inhibitors in targeting CD271+ SHH MB cells.